Stuttgart - Delayed Quote EUR

Harpoon Therapeutics Inc. (5HTA.SG)

21.00

0.00

(0.00%)

At close: March 8 at 8:58 PM GMT+1

Merck-Harpoon deal, Twilio, Crocs: Trending Tickers

Merck (MRK) is set to acquire Harpoon Therapeutics (HARP) in a deal valued at $680 million. Twilio (TWLO) Co-Founder Jeff Lawson steps down as CEO amid pressures from activist investor groups. Lastly, shares of footwear brand Crocs (CROX) have soared by over 20% on Monday after updating its guidance and full-year revenue forecasts for 2023. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

Yahoo Finance Video 3 months ago

CROX

TWLO

HARP
Merck to acquire Harpoon Therapeutics in $680M deal

Merck (MRK) is acquiring cancer drugmaker Harpoon Therapeutics (HARP) in a deal valued at $680 million.  In a statement, Dr. Dean Y. Li, Merck Research Laboratories President, said the deal will 'enhance' Merck's oncology pipeline and 'advance breakthrough science to help address the needs of people with cancer worldwide.'  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Nicholas Jacobino

Yahoo Finance Video 3 months ago

HARP

MRK
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

RAHWAY, N.J. & SOUTH SAN FRANCISCO, Calif., January 08, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.

Business Wire 3 months ago

MRK

HARP
Harpoon Therapeutics Strengthens Leadership Team

James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to t

GlobeNewswire 3 months ago

HARP
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU)

GlobeNewswire 4 months ago

HARP
$Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)$
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy • At the 12 mg dose, cohorts demonstrated favorable activity and safety profile:- 63% ORR; with 53% VGPR or better -- CRS reported in 16% of patients, no Grade 3 events, no ICANS - • Findings support further clinical development at the 12 mg RP2D SOUTH SAN FRANCISCO, Calif., Dec. 11,

GlobeNewswire 4 months ago

HARP
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung cancer (SCLC) and other neuroendocrine tumor types presented at ESMO 2023 HPN328 Phase 2 monotherapy dose(s) selection on track for year-end 2023 for discussion with regulators in 1H 2024 Data update of ongoing HPN328 Phase 1/2 trial expected in 1H 2024 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NE

GlobeNewswire 5 months ago

HARP
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma. The oral presentation will take place at the upcoming 65th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire 5 months ago

HARP
Harpoon Therapeutics Announces Up to $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million, with up to an additional approximately $50 million of gross proceeds upon cash exercise

GlobeNewswire 6 months ago

HARP
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in patients with small cell lung cancer (SCLC), including one confirmed complete response42% (5/12) confirmed response rate in other neuroendocrine tumor types, including two confirmed complete responses Generally well tolerated; cytokine release syndrome (CRS) most common, predominantly low-grade, with no

GlobeNewswire 6 months ago

HARP
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) presented at the European Society of Medical Oncol

GlobeNewswire 6 months ago

HARP
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) in a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place in Madrid, Spain from October

GlobeNewswire 6 months ago

HARP
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to be presented by the end of 2023 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the presentation of interim data for the 2.15 to 12 mg

GlobeNewswire 6 months ago

HARP
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced dosing of the first patients with small cell lung cancer (SCLC) in an ongoing Phase 1/2 trial of HPN328, a DLL3 targeting TriTAC®, in combination with atezolizumab (Tecentriq®). Harpoon previously entered a Master Clinical Supply Agreement with F. Hoffmann-La Roche for the supply of atezolizumab. Unde

GlobeNewswire 7 months ago

HARP
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA. The Agreement, which will terminate effective October 12, 2023, g

GlobeNewswire 7 months ago

HARP

Performance Overview

Return	5HTA.SG	S&P 500
YTD	+160.87%	+6.92%
1-Year	+303.85%	+25.26%
3-Year	-87.35%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Harpoon Therapeutics Inc. (5HTA.SG)

Merck-Harpoon deal, Twilio, Crocs: Trending Tickers

Merck to acquire Harpoon Therapeutics in $680M deal

Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Harpoon Therapeutics Strengthens Leadership Team

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Harpoon Therapeutics Announces Up to $150 Million Private Placement

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023

Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023

Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting

Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort

Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie

Performance Overview